Sentences with phrase «time pimobendan»
Not exact matches
In a study completed in the UK, Doberman Pinschers treated with pimobendan lived 6 times longer than those treated with an ACE inhibitor (329 days vs 50 days).7
https://www.epictrial.com/
In the QUEST Study, pimobendan significantly increased the survival time of dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD).
The EPIC Study showed that administration of pimobendan resulted in a 15 ‑ month delay in time to primary endpoint compared with dogs receiving placebo.
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST Study.
The QUEST Study established pimobendan as the new standard of treatment for dogs with congestive heart failure (CHF) caused by MMVD as it extended survival time.2 The veterinary community also sought to answer this question: Can pimobendan also delay the onset of clinical signs of CHF?
QUEST stands for Quality of Life and Extension of Survival Time, and was an international, multi-centre clinical study comparing 2 treatments used to combat CHF in dogs, pimobendan and an ACE inhibitor (benazepril hydrochloride).2
Median time to composite primary endpoint was 1228 days in the pimobendan group and 766 days in the placebo group (P = 0.0038).
In the EPIC Study, dogs in the pimobendan group experienced 60 % more time in asymptomatic stage B2 of heart disease and 10 % more life without CHF signs that impact quality of life (10 % more life without CHF was calculated based on an estimated lifespan for all small to medium ‑ sized dogs being 12.5 years.
Dogs in the standard - dose and low - dose pimobendan groups had significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P < 0.001).
At that time he was already on Pimobendan, Furosemide (12 mg / kg / d) and ACEI.
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.